调整保险状态和社区剥夺指数后早期激素受体阳性乳腺癌生存结局的种族差异评估:一项随机临床试验的事后分析
该研究为TAILORx随机临床试验的事后分析,纳入9719例激素受体阳性、ERBB2阴性、腋窝淋巴结阴性乳腺癌女性,中位随访96个月。多变量模型调整保险和社区剥夺指数后,黑人女性较白人女性无复发生存期和总生存期均显著更短,且早期停用内分泌治疗、保险和社区剥夺指数不能完全解释该差异。
要点
- 黑人女性较白人女性无复发生存期显著更短(HR 1.39;95%CI 1.05-1.84;P=.02)。
- 黑人女性较白人女性总生存期显著更短(HR 1.49;95%CI 1.10-2.99;P=.009)。
- 早期停用内分泌治疗、保险覆盖和社区剥夺指数不能完全解释观察到的差异。
核心结论
- 该随机临床试验事后分析提示,黑人乳腺癌女性较白人女性无复发生存期和总生存期显著更短。
- 早期停用内分泌治疗、肿瘤临床病理特征、保险覆盖和社区剥夺指数不能完全解释观察到的差异。
研究设计与样本
- 研究为TAILORx随机临床试验的事后分析,该试验于2006年4月7日至2010年10月6日开展。
- 纳入9719例激素受体阳性、ERBB2阴性、腋窝淋巴结阴性乳腺癌女性。
- 数据分析于2021年4月1日至10月22日进行,临床结局中位随访96个月。
主要发现
- 共纳入9719例女性:亚裔4.2%(n=405)、黑人7.1%(n=693)、白人84.3%(n=8189)、其他/未说明4.4%(n=403);9.1%(n=889)为西班牙裔或拉丁裔。
- 中位(SD)年龄为56(9.2)岁。
- 多变量模型调整研究入组时保险和NDI水平等因素后,黑人较白人无复发生存期显著更短(HR 1.39;95%CI 1.05-1.84;P=.02)。
- 多变量模型调整后,黑人较白人总生存期显著更短(HR 1.49;95%CI 1.10-2.99;P=.009)。
- 与私人保险相比,Medicare(HR 1.30;95%CI 1.01-1.68;P=.04)和Medicaid(HR 1.44;95%CI 1.01-2.05;P=.05)患者总生存期更短;无保险状态与临床结局无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Racial disparities in survival outcomes among Black women with hormone receptor-positive breast cancer have been reported. However, the association between individual-level and neighborhood-level social determinants of health on such disparities has not been well studied. OBJECTIVE: To evaluate the association between race and clinical outcomes (ie, relapse-free interval and overall survival) adjusting for individual insurance coverage and neighborhood deprivation index (NDI), measured using zip code of residence, in women with breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of 9719 women with breast cancer in the Trial Assigning Individualized Options for Treatment, a randomized clinical trial conducted from April 7, 2006, to October 6, 2010. All participants received a diagnosis of hormone receptor-positive, ERBB2-negative, axillary node-negative breast cancer. The present data analysis was conducted from April 1 to October 22, 2021. MAIN OUTCOMES AND MEASURES: A multivariate model was developed to evaluate the association between race and relapse-free interval and overall survival adjusting for insurance and NDI level at study entry, early discontinuation of endocrine therapy 4 years after initiation, and clinicopathologic characteristics of cancer. Median follow-up for clinical outcomes was 96 months. RESULTS: A total of 9719 women (4.2% [n = 405] Asian; 7.1% [n = 693] Black; 84.3% [n = 8189] White; 4.4% [n = 403] others/not specified) were included; 9.1% of included women [n = 889] were Hispanic or Latino. Median (SD) age was 56 (9.2) years. In multivariate models, Black race compared with White race was associated with statistically significant shorter relapse-free interval (hazard ratio [HR], 1.39; 95% CI, 1.05-1.84; P = .02) and overall survival (HR, 1.49; 95% CI, 1.10-2.99; P = .009), adjusting for insurance and NDI level at study entry and other factors. Although uninsured status was not associated with clinical outcomes, patients with Medicare (HR, 1.30; 95% CI, 1.01-1.68; P = .04) and Medicaid (HR, 1.44; 95% CI, 1.01-2.05; P = .05) had shorter overall survival compared with those with private insurance. Participants living in neighborhoods in the highest NDI quartile experienced shorter overall survival compared with those in the lowest quartile (HR, 1.34; 95% CI, 1.01-1.77; P = .04), regardless of self-identified race. CONCLUSIONS AND RELEVANCE: The findings of this post hoc analysis of a randomized clinical trial suggest that Black women with breast cancer have significantly shorter relapse-free interval and overall survival compared with White women. Early discontinuation of endocrine therapy, clinicopathologic characteristics, insurance coverage, and NDI do not fully explain the observed disparity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00310180.
引用
- Sadigh G, Gray RJ, Sparano JA, et al. Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 35175284. doi:10.1001/jamaoncol.2021.7656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。